Influence of Synovial Fluid Biochemical Markers on Clinical Outcomes Following Arthroscopic and Non-Arthroscopic Patients with Knee Osteoarthritis
Orthopedic Reviews · 13.03.2026 · 18
DOI: 10.52965/001c.158292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Orthopedic Reviews, online erschienen am 13.03.2026. Verfasst von Yanuarso und 6 weiteren Autor:innen. Beteiligte Einrichtung: Orthopedic Surgeon Gatot Soebroto Army Hospital. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Osteoarthritis (OA) is a degenerative joint disorder that causes pain, stiffness, and functional impairment. Conventional treatments relieve symptoms but do not restore cartilage, limiting long-term efficacy. Cell-based therapies, including mesenchymal stem cells (MSCs) and MSC-derived secretome, have emerged as promising strategies for cartilage regeneration. Object This study aimed to assess the therapeutic effects of UC-MSCs and UC-MSC-derived secretome in OA patients through both clinical outcomes and synovial fluid (SF) analyses.
Methods
Eligible participants were divided into two groups; group who underwent arthroscopy and group who did not. All the participants received an intra-articular injection consisting of an initial 2 mL dose of UC-MSC secretome, followed by 10 million UC-MSCs, and two additional 2 mL doses of secretome administered biweekly. Synovial fluid samples were collected at baseline and 12 weeks post-treatment, centrifuged to obtain the supernatant, and analyzed for inflammatory cytokines and matrix-degrading markers using multiplex and ELISA assays. Clinical evaluations were conducted at 6- and 12-months post-treatment.
Result
The results showed that UC-MSC therapy significantly improved functional outcomes in patients with knee osteoarthritis, as indicated by WOMAC scores up to six months. In vitro studies showed similar results, where co-culture of osteoarthritic synovial fluid-derived MSCs with UC-MSCs or UC-MSC secretome enhanced proliferation and differentiation while rapidly reducing pro-inflammatory cytokines (IL-1β, IFN-γ, IL-6, IL-12p70, IL-17A, IL-18) and MMPs (MMP1, MMP7, MMP13).
Conclusion
Our findings support a two-stage therapeutic strategy in which UC-MSC secretome first alleviates inflammation, followed by UC-MSCs to promote cartilage regeneration. Post-injection rehabilitation or repeated MSC dosing may further enhance treatment efficacy, highlighting the potential of MSC-based therapies for knee OA management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Orthopedic Surgeon Gatot Soebroto Army Hospital.
- Departement of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy Universitas Padjadjaran.
- Prodia StemCell Indonesia, Central Jakarta, Daerah Khusus Ibukota Jakarta 10430, Indonesia.
ORCID-Profile: Cynthia Retna Sartika, Karina Kalasuba, Rima Haifa
Zitieren
APA
Yanuarso, Devi, D. K., Lestari, K., Sartika, C. R., Kalasuba, K., Haifa, R., & Urbaningrum, L. M. (2026). Influence of Synovial Fluid Biochemical Markers on Clinical Outcomes Following Arthroscopic and Non-Arthroscopic Patients with Knee Osteoarthritis. Orthopedic Reviews, 18. https://doi.org/10.52965/001c.158292
Vancouver
Yanuarso, Devi DK, Lestari K, Sartika CR, Kalasuba K, Haifa R, et al. Influence of Synovial Fluid Biochemical Markers on Clinical Outcomes Following Arthroscopic and Non-Arthroscopic Patients with Knee Osteoarthritis. Orthopedic Reviews. 2026;18. doi:10.52965/001c.158292
BibTeX
@article{Yanuarso2026,
author = {Yanuarso and Devi, Ditta Kalyani and Lestari, Keri and Sartika, Cynthia Retna and Kalasuba, Karina and Haifa, Rima and Urbaningrum, Lestari Mahardika},
title = {Influence of Synovial Fluid Biochemical Markers on Clinical Outcomes Following Arthroscopic and Non-Arthroscopic Patients with Knee Osteoarthritis},
journal = {Orthopedic Reviews},
year = {2026},
volume = {18},
doi = {10.52965/001c.158292}
}
EUVIMED